Relief Therapeutics Holding SA
RLFTF evidence brief
What we can confirm
- Market Cap:
- $2.8M
What it means
What to watch
Prepared research question
What matters most for RLFTF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RLFTF
Relief Therapeutics Holding SA is a Swiss commercial-stage biopharmaceutical company focused on developing treatments for rare diseases, with a limited number of approved products and a pipeline of candidates in clinical development.
Key risk: Going concern risk
Market Cap
$2.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 4 clinical trials for Relief Therapeutics Holding SA.
Relief Therapeutics Holding SA is a Swiss commercial-stage biopharmaceutical company focused on developing treatments for rare diseases, with a limited number of approved products and a pipeline of candidates in clinical development.
- Relief Therapeutics is a Swiss commercial-stage biopharmaceutical company targeting rare diseases with established products and capital-efficient clinical trials [sec · filed 2023-05-12].
- As of December 31, 2023, the company had cash and cash equivalents of CHF 14.6 million and expects to fund operations into 2026 [sec · filed 2024-04-30].
- The company reported a net loss of approximately CHF 98.2 million for the year ended December 31, 2023, and accumulated losses of approximately CHF 218.3 million as of that date [sec · filed 2024-04-30].
- Relief Therapeutics has a small number of approved products, including OLPRUVA™ (ACER-001) and PKU GOLIKE®, and relies on partnerships for commercialization [sec · filed 2024-04-30].
- The company has a history of operating losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern [sec · filed 2024-04-30].
What works
- The company targets established products with proven safety and efficacy, allowing for relatively short, capital-efficient clinical trials with clear endpoints [sec · filed 2023-05-12].
- Relief Therapeutics has a commercial-stage presence with a limited number of approved products generating sales, such as OLPRUVA™ and PKU GOLIKE® [sec · filed 2024-04-30].
- The company has licensed products and entered into commercialization agreements, such as with Eton Pharmaceuticals for PKU GOLIKE® in the United States [sec · filed 2024-04-30].
What to weigh
- The company has a history of operating losses, with a net loss of CHF 98.2 million in 2023 and accumulated losses of CHF 218.3 million, raising substantial doubt about its ability to continue as a going concern [sec · filed 2024-04-30].
- Cash and cash equivalents were only CHF 14.6 million as of December 31, 2023, and the company may need additional funding to continue operations beyond its current projections [sec · filed 2024-04-30].
- The company depends heavily on the success of its product candidates, and failure in clinical development or regulatory approval could materially adversely affect its business [sec · filed 2024-04-30].
- Relief Therapeutics has a small number of approved products with limited sales volume, and significantly higher product revenues depend on successful development and commercialization of its pipeline [sec · filed 2024-04-30].
From the filings
Quoted directly from source documents.
Cash position and runway into 2026
“As of December 31, 2023, we had cash and cash equivalents of CHF 14.6 million. Based on current financial projections and available cash, we believe that we have sufficient resources to fund operations into 2026.”
SEC filings · April 30, 2024
Net loss and accumulated deficit
“We incurred a net loss (defined as net loss attributable to owners of the Company) of approximately CHF 98.2 million for the year ended December 31, 2023 and had accumulated losses at consolidation level of approximately CHF 218.3 million as of December 31, 2023.”
SEC filings · April 30, 2024
Going concern uncertainty
“Our recurring losses, negative cash flows and significant accumulated deficit raise substantial doubt regarding our ability to continue as a going concern.”
SEC filings · April 30, 2024
Strategy of targeting established products
“We target established products with a proven history of safety and efficacy and either initial human therapeutic activity, proof-of-concept or a strong scientific rationale, allowing for relatively short, capital-efficient clinical trials with clear endpoints.”
SEC filings · May 12, 2023
Risks & what to watch (4)›
Key risks
- Going concern risk — Recurring losses and negative cash flows raise substantial doubt about the company's ability to continue as a going concern [sec · filed 2024-04-30].
- Dependence on pipeline success — The company depends heavily on successful clinical development and regulatory approval of its product candidates [sec · filed 2024-04-30].
- Limited product revenue — Only a small number of approved products generate limited sales, and significantly higher revenues depend on pipeline success [sec · filed 2024-04-30].
- Need for additional capital — The company will require additional capital to develop and commercialize product candidates, and failure to obtain funding may delay or reduce programs [sec · filed 2024-04-30].
What to watch
- Cash runway and ability to secure additional financing beyond 2026 [sec · filed 2024-04-30].
- Progress of clinical trials for product candidates and any regulatory submissions [sec · filed 2024-04-30].
- Commercial performance of approved products like OLPRUVA™ and PKU GOLIKE® [sec · filed 2024-04-30].
- Potential NASDAQ listing and its impact on liquidity and shareholder base [sec · filed 2023-05-12].
Sources: SEC filings · Generated September 17, 2026 · How we verify sources →
Run Relief Therapeutics Holding SA through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Relief Therapeutics Holding SA facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Relief Therapeutics Holding SA?
Relief Therapeutics Holding SA is a Swiss commercial-stage biopharmaceutical company focused on developing treatments for rare diseases, with a limited number of approved products and a pipeline of candidates in clinical development.
Who is the CEO of Relief Therapeutics Holding SA?
Mr. Zachery W. Henderson is the chief executive officer of Relief Therapeutics Holding SA (RLFTF).
Where is Relief Therapeutics Holding SA headquartered?
Relief Therapeutics Holding SA (RLFTF) is headquartered in Geneva, Switzerland.
What therapeutic areas does Relief Therapeutics Holding SA focus on?
Relief Therapeutics Holding SA develops therapies across Oncology, Rare Disease, Neurology, Pain, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.